Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors
Idera Pharmaceuticals, Inc. (IDRA)
Last idera pharmaceuticals, inc. earnings: 11/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.iderapharma.com/investor-overview
Company Research
Source: GlobeNewswire
EXTON, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a toll-like receptor 9 (TLR9) agonist, in combination with nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and ipilimumab, a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody for the treatment of solid tumors. The primary objective of this phase 2, open-label, global, study is to demonstrate efficacy (measured by overall response rate [ORR] based on RECIST v.1.1). Secondary and exploratory objectives include safety, tolerability, immunogenicity and translational data evaluations. The initial cohort of the trial will be patients with immunotherapy-naive Microsatellite Stable Colorectal Cancer (MSS-CRC). The second planned cohort of ILLUMINATE-206 will focus on treating patients with anti-PD(L)-1 refractory Squamous Cell Carcinoma of the Head and Neck (RM-SCCH
Show less
Read more
Impact Snapshot
Event Time:
IDRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IDRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IDRA alerts
High impacting Idera Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics